| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT02913716 | Healthy Subjects | Drug: defactinib | Verastem, Inc. | Phase 1 | 2015-08-01 | 2017-01-26 |
| NCT02943317 | Epithelial Ovarian Cancer | Drug: Part A - VS-6063|Drug: Part A - Avelumab | Verastem, Inc. | Phase 1 | 2016-10-01 | 2017-01-30 |
| NCT02004028 | Malignant Pleural Mesothelioma | Drug: VS-6063 | Verastem, Inc. | Phase 2 | 2013-12-01 | 2017-02-01 |
| NCT01943292 | Non Hematologic Cancers | Drug: Defactinib | Verastem, Inc. | Phase 1 | 2013-09-02 | 2017-01-26 |
| NCT02758587 | Carcinoma, Non-small-cell Lung|Mesothelioma|Pancreatic Neoplasms | Drug: Defactinib|Drug: Pembrolizumab | NHS Greater Glasgow and Clyde|University of Glasgow|Cancer Research UK|Merck Sharp & Dohme Corp.|Verastem, Inc.|University of Edinburgh|University of Southampton|University of Leicester|Queen's University, Belfast | Phase 1|Phase 2 | 2016-06-01 | 2016-06-14 |
| NCT01870609 | Malignant Pleural Mesothelioma | Drug: defactinib (VS-6063)|Drug: Placebo | Verastem, Inc. | Phase 2 | 2013-09-01 | 2017-01-26 |
| NCT02546531 | Advanced Solid Tumors|Solid Tumors|Pancreatic Cancer | Biological: Defactinib|Biological: Pembrolizumab|Drug: Gemcitabine | Washington University School of Medicine | Phase 1 | 2016-02-03 | 2017-02-22 |
| NCT01778803 | Ovarian Cancer | Drug: defactinib (VS-6063)|Drug: Paclitaxel | Verastem, Inc. | Phase 1 | 2013-01-01 | 2015-06-01 |
| NCT01951690 | Non Small Cell Lung Cancer|Lung Cancer | Drug: defactinib (VS-6063) | Verastem, Inc. | Phase 2 | 2013-09-01 | 2017-02-01 |
